(IQV) IQVIA Holdings - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NYSE (USA) | Market Cap: 28.221m USD | Total Return: 21.6% in 12m
Avg Turnover: 279M
EPS Trend: -11.8%
Qual. Beats: 0
Rev. Trend: 97.2%
Qual. Beats: 2
Warnings
Below Avwap Earnings
Tailwinds
Garp
IQVIA Holdings Inc. (IQV) is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Formed by the merger of IMS Health and Quintiles, the company operates through three primary segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Its business model relies on a massive proprietary data pool to assist pharmaceutical and biotechnology firms in drug development, clinical trial management, and commercial execution.
The company operates within the Life Sciences Tools & Services sub-industry, a sector characterized by high barriers to entry due to complex regulatory requirements and the specialized nature of clinical data management. As a Contract Research Organization (CRO), IQVIA benefits from the increasing trend of pharmaceutical companies outsourcing R&D to reduce fixed costs and accelerate time-to-market for new therapies. This model integrates cloud-based applications with real-world evidence to track prescribing trends and patient outcomes across global markets.
Investors looking for deeper insights into these industry trends and company valuation may find it useful to explore the data available on ValueRay. IQVIA remains headquartered in Durham, North Carolina, serving a diverse client base that includes medical device manufacturers and consumer health providers.
- Biotech funding levels dictate clinical trial demand and R&D backlog growth
- Real-world data adoption expands high-margin Technology and Analytics segment revenue
- Global drug development outsourcing trends drive Research and Development Solutions volume
- Rising labor costs for specialized clinical staff pressure consolidated operating margins
- Regulatory shifts in drug pricing and data privacy impact commercial intelligence demand
| Net Income: 1.39b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.09 > 1.0 |
| NWC/Revenue: -12.68% < 20% (prev -8.18%; Δ -4.50% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.70b > Net Income 1.39b |
| Net Debt (14.1b) to EBITDA (3.51b): 4.02 < 3 |
| Current Ratio: 0.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (169.8m) vs 12m ago -4.28% < -2% |
| Gross Margin: 26.11% > 18% (prev 0.33%; Δ 2.58k% > 0.5%) |
| Asset Turnover: 58.36% > 50% (prev 56.72%; Δ 1.64% > 0%) |
| Interest Coverage Ratio: 3.10 > 6 (EBITDA TTM 3.51b / Interest Expense TTM 756.0m) |
| A: -0.07 (Total Current Assets 6.22b - Total Current Liabilities 8.33b) / Total Assets 29.7b |
| B: 0.26 (Retained Earnings 7.70b / Total Assets 29.7b) |
| C: 0.08 (EBIT TTM 2.35b / Avg Total Assets 28.5b) |
| D: 0.78 (Book Value of Equity 18.1b / Total Liabilities 23.3b) |
| Altman-Z'' = 1.75 = BBB |
| DSRI: 1.10 (Receivables 3.92b/3.31b, Revenue 16.6b/15.5b) |
| GMI: 1.26 (GM 26.11% / 32.98%) |
| AQI: 1.01 (AQ_t 0.76 / AQ_t-1 0.76) |
| SGI: 1.07 (Revenue 16.6b / 15.5b) |
| TATA: -0.04 (NI 1.39b - CFO 2.70b) / TA 29.7b) |
| Beneish M = -2.69 (Cap -4..+1) = A |
As of May 23, 2026, the stock is trading at USD 168.02 with a total of 2,081,567 shares traded.
Over the past week, the price has changed by -0.72%,
over one month by -4.17%,
over three months by +3.44% and
over the past year by +21.63%.
IQVIA Holdings has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy IQV.
- StrongBuy: 14
- Buy: 2
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 228.6 | 36.1% |
P/E Forward = 13.21
P/S = 1.6968
P/B = 4.5077
P/EG = 0.6809
Revenue TTM = 16.6b USD
EBIT TTM = 2.35b USD
EBITDA TTM = 3.51b USD
Long Term Debt = 14.0b USD (from longTermDebt, last quarter)
Short Term Debt = 1.84b USD (from shortTermDebt, last quarter)
Debt = 16.1b USD (corrected: LT Debt 14.0b + ST Debt 1.84b) + Leases 232.0m
Net Debt = 14.1b USD (calculated: Debt 16.1b - CCE 1.95b)
Enterprise Value = 42.3b USD (28.2b + Debt 16.1b - CCE 1.95b)
Interest Coverage Ratio = 3.10 (Ebit TTM 2.35b / Interest Expense TTM 756.0m)
EV/FCF = 15.85x (Enterprise Value 42.3b / FCF TTM 2.67b)
FCF Yield = 6.31% (FCF TTM 2.67b / Enterprise Value 42.3b)
FCF Margin = 16.07% (FCF TTM 2.67b / Revenue TTM 16.6b)
Net Margin = 8.33% (Net Income TTM 1.39b / Revenue TTM 16.6b)
Gross Margin = 26.11% ((Revenue TTM 16.6b - Cost of Revenue TTM 12.3b) / Revenue TTM)
Gross Margin QoQ = 32.64% (prev 6.69%)
Tobins Q-Ratio = 1.43 (Enterprise Value 42.3b / Total Assets 29.7b)
Interest Expense / Debt = 4.71% (Interest Expense 756.0m / Debt 16.1b)
Taxrate = 17.99% (59.0m / 328.0m)
NOPAT = 1.92b (EBIT 2.35b * (1 - 17.99%))
Current Ratio = 0.75 (Total Current Assets 6.22b / Total Current Liabilities 8.33b)
Debt / Equity = 2.58 (Debt 16.1b / totalStockholderEquity, last quarter 6.22b)
Debt / EBITDA = 4.02 (Net Debt 14.1b / EBITDA 3.51b)
Debt / FCF = 5.28 (Net Debt 14.1b / FCF TTM 2.67b)
Total Stockholder Equity = 6.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.86% (Net Income 1.39b / Total Assets 29.7b)
RoE = 22.46% (Net Income TTM 1.39b / Total Stockholder Equity 6.17b)
RoCE = 11.64% (EBIT 2.35b / Capital Employed (Equity 6.17b + L.T.Debt 14.0b))
RoIC = 8.30% (NOPAT 1.92b / Invested Capital 23.2b)
WACC = 7.43% (E(28.2b)/V(44.3b) * Re(9.46%) + D(16.1b)/V(44.3b) * Rd(4.71%) * (1-Tc(0.18)))
Discount Rate = 9.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.01 | Cagr: -3.58%
[DCF] Terminal Value 77.97% ; FCFF base≈2.47b ; Y1≈2.83b ; Y5≈4.16b
[DCF] Fair Price = 290.9 (EV 62.7b - Net Debt 14.1b = Equity 48.6b / Shares 166.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -11.78 | EPS CAGR: -1.02% | SUE: 0.34 | # QB: 0
Revenue Correlation: 97.24 | Revenue CAGR: 4.15% | SUE: 1.50 | # QB: 2
EPS current Quarter (2026-06-30): EPS=3.03 | Chg30d=+0.46% | Revisions=+9% | Analysts=18
EPS next Quarter (2026-09-30): EPS=3.24 | Chg30d=+1.73% | Revisions=+68% | Analysts=18
EPS current Year (2026-12-31): EPS=12.80 | Chg30d=+0.79% | Revisions=+58% | GrowthEPS=+7.4% | GrowthRev=+6.0%
EPS next Year (2027-12-31): EPS=14.19 | Chg30d=+0.53% | Revisions=+42% | GrowthEPS=+10.8% | GrowthRev=+5.8%
[Analyst] Revisions Ratio: +68%